Clinical Trial Update: A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for RC48-ADC in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED